The Complement System: A Prey of Trypanosoma cruzi

Kárita C. F. Lidani*, Lorena Bavia†, Altair R. Ambrosio† and Iara J. de Messias-Reason*

Laboratory of Molecular Immunopathology, Clinical Hospital, Federal University of Paraná, Curitiba, Brazil

Trypanosoma cruzi is a protozoan parasite known to cause Chagas disease (CD), a neglected sickness that affects around 6–8 million people worldwide. Originally, CD was mainly found in Latin America but more recently, it has been spread to countries in North America, Asia, and Europe due to the international migration from endemic areas. Thus, at present CD represents an important concern of global public health. Most of individuals that are infected by T. cruzi may remain in asymptomatic form all lifelong, but up to 40% of them will develop cardiomyopathy, digestive mega syndromes, or both. The interaction between the T. cruzi infective forms and host-related immune factors represents a key point for a better understanding of the physiopathology of CD. In this context, the complement, as one of the first line of host defense against infection was shown to play an important role in recognizing T. cruzi metacyclic trypomastigotes and in controlling parasite invasion. The complement consists of at least 35 or more plasma proteins and cell surface receptors/regulators, which can be activated by three pathways: classical (CP), lectin (LP), and alternative (AP). The CP and LP are mainly initiated by immune complexes or pathogen-associated molecular patterns (PAMPs), respectively, whereas AP is spontaneously activated by hydrolysis of C3. Once activated, several relevant complement functions are generated which include opsonization and phagocytosis of particles or microorganisms and cell lysis. An important step during T. cruzi infection is when intracellular trypomastigotes are released to bloodstream where they may be target by complement. Nevertheless, the parasite uses a sequence of events in order to escape from complement-mediated lysis. In fact, several T. cruzi molecules are known to interfere in the initiation of all three pathways and in the assembly of C3 convertase, a key step in the activation of complement. Moreover, T. cruzi promotes secretion of plasma membrane-derived vesicles from host cells, which prevent the activity of C3 convertase C4b2a and thereby may hinder complement. In this review, we aim to present an overview on the strategies used by T. cruzi in order to circumvent the activation of complement and, consequently, its biological effects.

Keywords: Trypanosoma cruzi, complement system, complement regulatory proteins, evasion mechanism, innate immunity

INTRODUCTION

Trypanosoma cruzi is a hemoflagellate parasite of the order Kinetoplastida and Trypanosomatidae family (Levine et al., 1980) that causes CD. The parasite presents complex mechanisms of surveillance in the mammalian host and exerts direct influence on the course of CD (Watanabe Costa et al., 2016). CD is responsible for more expressive morbimortality than any other parasitic
Trypanosoma cruzi AND CHAGAS DISEASE

T. cruzi Life Cycle

Trypanosoma cruzi infection occurs predominantly via vectorial transmission by triatomine bugs of the genera Triatoma, Rhodnius, and Panstrongylus. These bugs suck the blood of vertebrates infected with trypomastigotes, and this initiates the parasite life cycle. Once ingested by the insect vector, trypomastigotes are transformed in the anterior midgut either into spheromastigote or epimastigote forms. Epimastigotes multiply in the midgut and attach to the perimicrovillar membranes of the triatome intestinal cells. At the most posterior region of the vector’s intestine and at the rectum, many epimastigotes detach from the intestinal surface and become infective metacyclic trypomastigotes, which are then released with feces and urine during blood meals. However, metacyclic trypomastigotes are not able to penetrate the intact host skin and enter through the rubbing or scratching of the bite wound, or through permisive mucosal or conjunctival surfaces at the inoculation site. Recruitment and fusion of the host lysosome with the parasite involves the formation of a parasitophorous endocytic vacuole, which is needed for parasite invasion of fibroblasts, macrophages, and epithelial cells (Souza et al., 2010; Nogueira et al., 2015). Subsequently, the parasite promotes enzymatic lysis of the vacuole membrane, differentiating into intracellular amastigotes, which after nine cycles of binary division become trypomastigotes that are eventually released into the circulation as bloodstream trypomastigotes (Dvorak and Hyde, 1973; Dvorak and Howe, 1976). These either infect new cells or are taken up by a new insect vector during a blood meal, repeating the parasite cycle.

Once in the bloodstream of a mammalian host, T. cruzi is able to infect several cell types from a variety of tissues thereby spreading to new infection sites where they differentiate into intracellular amastigotes (Watanabe Costa et al., 2016) (Figure 1). Besides vectorial transmission, T. cruzi can also be transmitted through blood transfusion, organ transplantation, transfusationally, the ingestion of contaminated food or drinks, or by accidental exposure; however, the physiopathological mechanisms of such transmissions are still unclear.

Chagas Disease

Several clinical manifestations may result in humans from T. cruzi infection. This initiates with an acute phase that last for about 2 months characterized by high parasitemia. In this stage, the diagnosis may be achieved by direct visualization of the parasite in blood and by the detection of IgG antibodies against T. cruzi antigens. Although most acute cases are oligosymptomatic or asymptomatic, initial dermatologic manifestations resulting in a skin lesion (chagoma), eyelid edema and conjunctivitis (Romãa sign), or generalized morbilliform eruption (schitzotrypanides) may be present (Nunes et al., 2013). Other symptoms may include anorexia, fever, headache, dyspnea, abdominal pain, cough, hepatosplenomegaly, rash,
FIGURE 1 | Life cycle of Trypanosoma cruzi. Transmission is initiated by insect vectors that defecate after a blood meal and release metacyclic trypomastigotes near the bite wound. This infective stage is characterized by the invasion of host cells by trypomastigotes forming the parasitophorous vacuole, from which they subsequently escape, differentiate into amastigotes, and replicate in the cytosol. The amastigotes then divide, differentiate into trypomastigotes, and upon rupture of the cell spread the infection to tissues. Trypomastigotes reach the bloodstream, where they are eventually taken up by the insect vector or infect new cells. In the triatomine bugs, trypomastigotes differentiate into spheromastigotes becoming initially short epimastigotes (mid-log). After migration to the bug’s hindgut, elongate epimastigotes (late-log) attach to the waxy gut cuticle and give rise to infectious metacyclic trypomastigotes, completing the parasite life cycle.

painful nodules, generalized body swelling, and myocarditis (Hidron et al., 2010; Malik et al., 2015).

Following the acute phase, most infected people enter into a prolonged asymptomatic indeterminate form of the chronic disease and will never develop Chagas-related symptoms. However, after 10–30 years of infection approximately 30–40% of chronically infected people will present some clinical manifestations such as cardiomyopathy (20–30%), digestive commitment (10–15%) or both (1–5%) (Rassi and Marin-Neto, 2010). Chronic cardiomyopathy represents the most severe and life-threatening manifestation of human CD, ranging from asymptomatic electrocardiogram abnormalities to congestive heart failure, arrhythmias, and/or thromboembolic events (Biolo et al., 2010) that are associated with high morbidity and mortality. In fact, mortality related with CD is generally due to cardiovascular involvement, with approximately 12,000 deaths every year (Salvatella et al., 2013), with sudden death accounting for around 60%, heart failure 25–30% and stroke 10–15% (Rassi et al., 2001).

Standard approaches for CD diagnosis in the chronic phase require at least two different serological tests, generally using ELISA and IFA (Bern et al., 2007). Additionally, amplification of parasite DNA by PCR may be employed in some uncertain cases (Schijman et al., 2011) (Figure 2).

THE COMPLEMENT SYSTEM

The complement system constitutes a key component of innate immunity with a significant role in the first line of defense against invading microbes. It comprises more than 35 plasma and cell membrane receptor/regulator proteins that become activated mainly by three pathways: lectin (LP), classical (CP), and alternative (AP), resulting in important biological responses such as inflammation, phagocytosis, and lysis of pathogens (Ricklin et al., 2010). Activation of complement and its potent inflammatory response through the production of molecules with anaphylatoxin activity was first demonstrated by Dias da Silva and Lepow (1967). The functional role in vascular permeability, histamine release from mast cells and contraction of smooth muscle of the anaphylatoxins (C4a, C3a, and C5a) was subsequently reported (Dias da Silva and Lepow, 1967; Dias da Silva et al., 1967; Cochrane and Müller-Eberhard, 1968). Besides inflammatory response, the complement also plays an important role in the solubilization and removal of circulating immune complexes to avoid their deposition, which could result in tissue injury (Miller and Nussenzweig, 1974). In addition, the complement system links the innate and acquired responses through the activation of B lymphocytes and synthesis of immunoglobulins (Walport, 2001; Ricklin et al., 2010, 2016). Furthermore, complement is involved in the opsonization of
FIGURE 2 | Natural course of human T. cruzi infection. T. cruzi transmission can occur by (1) vectorial (2) blood transfusion or organ transplantation, (3) oral, or (4) congenital routes. The incubation period lasts for 5–10 days after human contamination with T. cruzi from triatomines, which is followed by the acute phase of Chagas disease that lasts 4–8 weeks. This phase is characterized by circulating trypomastigotes, which can be visualized in the blood and IgM anti-T. cruzi antibodies can be detected after 10 days of infection. Most patients have non-specific symptoms, such as fever and anorexia, or are asymptomatic, and may develop inflammation and swelling at the site of inoculation in the skin or conjunctiva, characterizing chagoma and Romaña’s signal, respectively. The chronic phase begins once parasitemia falls below detectable levels by microscopy, usually 4 to 8 weeks after the onset of infection, and therefore diagnosis is based on the detection of anti-T. cruzi IgG antibodies or molecular tests. In this phase, most infected people enter a prolonged asymptomatic form known as the indeterminate form and will never develop Chagas-related symptoms. However, after 10–30 years around 30–40% of chronically infected people will present some clinical manifestations including cardiac, digestive, or cardiodigestive complaints.

Complement is activated mainly by three pathways, LP, CP, and AP, which lead to the generation of effector molecules, self-amplification, and the induction of immune signaling (Ricklin et al., 2010). The LP can be triggered through the binding of PRMs, such as MBL, ficolins (Ficolin-1 [or M-ficolin], Ficolin-2 [or L-ficolin], and Ficolin-3 [or H-ficolin]) and CL-K1, to PAMPs on the pathogen’s surface (Beltrame et al., 2015). Whereas carbohydrate-recognition domains in the MBL molecule bind to sugar moieties on the pathogen’s surface (such as D-mannose, glucose, L-fucose, and GlcNAc) (Weis et al., 1992), the three human ficolins bind to PAMPs by fibrinogen-like recognition domains and exhibit differences in their binding specificities (Gout et al., 2010). For instance, Ficolin-1 recognizes N-acetylated compounds (such as GlcNAc and N-acetylglactosamine [GalNAc]) (Frederiksen et al., 2005), O-acetylated and glycan compounds containing sialic acid (Gout et al., 2010). Ficolin-2 also recognizes N-acetylated compounds and capsulated strains of bacteria (Frederiksen et al., 2005; Gout et al., 2010), while Ficolin-3 binds GalNAc, GlcNAc, D-fucose as mono/oligosaccharides and lipopolysaccharides (Sugimoto et al., 1998). In addition, CL-K1 senses mannose and fucose-containing microbial derived products (Keshi et al., 2006). Following the binding of MBL, ficolins, or CL-K1 to PAMPs, the LP is initiated by the activation of MASP-1 and MASP-2 resulting in active forms (Kjaer et al., 2013) that cleave C4 in C4a and C4b, and C2 in C2a and C2b, culminating with the formation of the LP C3 convertase (C4b2a) and C5 convertase (C4b2aC3b) (Walport, 2001; Ricklin et al., 2010; Merle et al., 2015).

The activation of the CP depends mainly on the interaction of C1 with antigen-antibody complexes or alternatively, by PAMPs (lipopolysaccharides and porins from Gram-negative bacteria), phospholipids, apoptotic cells (phosphatidylserine) or pentraxins (C-reactive protein and pentraxin 3), among others (Alberti et al., 1993; Kishore et al., 2004). The C1 complex is formed of one C1q molecule and two molecules each of C1r and C1s (C1qC1r2C1s2). C1q initiates the activation of the CP by binding to CH3 or CH2 Fc domains of IgM and IgG, respectively, inducing a conformational change in C1q. This leads to the activation of C1r and C1s, and serine proteases that cleave C4 and C2 (Lörincz et al., 2000), forming the CP C3 and C5 convertases (C4b2a and C4C2aC3b), similar to those generated in the LP (Ricklin et al., 2010).

The activation of the AP starts with spontaneous hydrolysis of the thiol-ester bond in C3 α-chain generating C3(H2O). This molecule exhibits a reactive site for the plasma protein FB, forming the complex C3(H2O)B. In this condition, FB can be cleaved by FD in Bα and Bb. The Bb fragment remains bound to C3(H2O), forming the first C3 convertase of AP (C3(H2O)Bb), which now exhibits serine protease activity cleaving further C3 molecules into C3a and C3b. Like C3(H2O), C3b exhibits reactive sites for FB binding allowing its cleavage by FD, resulting in the second C3 convertase of this pathway, C3bBb. Additionally, C3 binds to C3bBb forming C3bBbC3b, a complex with C5 convertase activity (Walport, 2001; Ricklin et al., 2010).
Once all three pathways are activated, the C5 convertases formed by both CP/LP (C4b2a3b) and AP (C3bBb3b) cleave C5 in C5a and C5b. The fragment C5b binds to C6, forming a stable complex C5b6, which recruits C7 resulting in a hydrophobic complex that targets cell membranes (mC5b-7). After C8 is incorporated to mC5b-7, the C5b678 complex becomes inserted in the cell membrane. Then, 12–18 copies of the C9 molecule polymerize forming the MAC. This pore-forming ring structure (C5b678(9)n) gets inserted into the cell as a transmembrane channel, favoring ionic imbalance and an increase in intracellular volume leading to membrane cell disruption (Kondos et al., 2010).

Since undesirable activation of complement may lead to inflammation and tissue damage, an effective and accurate system of regulatory molecules is required for the maintenance of its homeostasis. In this context, a variety of membrane-bound inhibitory proteins (such as CR1, CD59, CD46, and DAF or CD55) downregulate local complement activation, protecting host cells from unwanted complement lysis (Carroll and Sim, 2011; Noris and Remuzzi, 2013). In addition, several plasma regulator proteins (such as Factor H, Factor I, C1-INH, C4BP, and vitronectin) control soluble activated complement components and complexes (Carroll and Sim, 2011; Noris and Remuzzi, 2013). In general, either excessive or defective complement activation may be implicated in the pathogenesis of some conditions including autoimmune, chronic inflammatory, and infectious diseases (Ricklin and Lambris, 2013).

**Complement Activation by T. cruzi**

The interaction of complement with T. cruzi is a principal step in the immediate immune response of the host against the parasite. However, it is important to consider that this interaction is dependent on the evolutive forms of the parasite. Experimental studies showed that complement can be activated by amastigote (Iida et al., 1989), epimastigote (Nogueira et al., 1975), and trypomastigote forms (Kipnis et al., 1985), but only non-infective (Iida et al., 1989), epimastigote (Nogueira et al., 1975), and studies showed that complement can be activated by amastigote dependent on the evolutive forms of the parasite. Experimental however, it is important to consider that this interaction is dependent on the evolutive forms of the parasite. The success of T. cruzi infection depends on a series of complex mechanisms that enable the parasite to evade the host immune response. In fact, T. cruzi employs a range of strategies to escape the effects of both innate and adaptive immunity. A crucial step occurs during the first seconds of infection when trypomastigotes needs to circumvent the harmful lytic attack of complement (Sacks and Sher, 2002). During differentiation from epimastigote to metacyclic trypomastigote forms inside the insect vector, the parasite undergoes a series of morphological and physiological changes that confers the capacity to evade the lytic effect of complement. The mechanism controlling this resistance mainly involves the expression of complement binding

During the differentiation cycle from non-infective/complement susceptible to infective/complement resistance forms, trypomastigotes acquire the ability to circumvent complement lysis by TcCRT, TcCRP, TcCRIT, gp58/68, and T-DAF molecules. At the first stages of T. cruzi infection (seconds after infection), complement can be initially activated by the LP and AP since both pathways do not depend on a specific antibody response (Cestari et al., 2013). Thus, trypomastigotes can immediately be targeted by complement after accessing the host bloodstream. A wide range of carbohydrates (such as GalNAC and GlcNAc) anchored by glycosylphosphatidylinositol in the outer leaflet of T. cruzi plasma membrane (Lederkremer and Bertello, 2001; Buscaglia et al., 2006) can be recognized by PAMP sensor molecules, such as MBL and ficolins (Cestari et al., 2009; Cestari and Ramirez, 2010) leading to the activation of MASPs. Then, the serine protease MASP-2 cleaves C2 and C4 generating LP C3 convertase formation that activates C3 to form C3b, contributing to the AP amplification loop with simultaneous LP and AP activation (Ricklin et al., 2010; Cestari et al., 2013). In addition, the activation of the AP can also take place spontaneously by hydrolysis of C3, which leads to the generation of C3 convertase and C3 cleavage. However, deposition of C3b on trypomastigotes may contribute to T. cruzi internalization by CR1 (van Lookeren et al., 2007). Both LP and AP can be continually activated, not only at the first stages of T. cruzi infection, but also during the course of chronic CD (Lidani et al., 2015). At a later stage of T. cruzi infection (days post-infection), CP becomes activated when anti-trypomastigote-specific IgM and IgG antibodies are produced allowing C1q binding and the activation of C1r and C1s serine proteases that cleave C4 and C2 forming the CP C3 convertase. Although during T. cruzi infection complement is activated by these three pathways, the process is interrupted at the C3 convertase level by complement regulatory proteins derived from trypomastigotes that cause abrogation of the terminal pathway and MAC formation. This evasion from complement lysis allows trypomastigote cell invasion and tissue spreading driving the infection toward chronic disease.

**COMPLEMENT EVASION STRATEGIES USED BY T. cruzi**

The success of T. cruzi infection depends on a series of complex mechanisms that enable the parasite to evade the host immune response. In fact, T. cruzi employs a range of strategies to escape the effects of both innate and adaptive immunity. A crucial step occurs during the first seconds of infection when trypomastigotes needs to circumvent the harmful lytic attack of complement (Sacks and Sher, 2002). During differentiation from epimastigote to metacyclic trypomastigote forms inside the insect vector, the parasite undergoes a series of morphological and physiological changes that confers the capacity to evade the lytic effect of complement. The mechanism controlling this resistance mainly involves the expression of complement binding
Activation of complement system by *Trypanosoma cruzi* epimastigote forms. MBL and ficolins recognize and bind to glycoproteins and carbohydrates present on the *T. cruzi* epimastigote surface initiating the LP. This interaction leads to conformational changes in MBL and ficolins and activation of MASP-1 followed by MASP-2 which cleavages C4 into C4a and C4b and C2 into C2a and C2b, generating C3 convertase (C4b2a). In presence of specific anti-*T. cruzi* antibodies, C1q molecules recognize and bind to IgM and IgG on the parasite’s surface initiating the CP. Subsequently, C1q suffers conformational changes and activates C1r, which cleaves and activates C1s that subsequently cleaves C4 and C2 generating C3 convertase (C4b2a), as in the LP convertase. When C3b binds to C4b2a, the complex forms C4b2aC3b, with C5 convertase activity. The AP is initiated by the generation of C3(H2O) after spontaneous hydrolysis of C3, or as a consequence of loop amplification triggered during LP and CP activation. Since FB binds to C3(H2O), FB can be cleaved by FD in Bb and Bb. The Bb fragment remains bound to C3(H2O) forming the first C3 convertase of AP (C3(H2O)Bb), which cleaves C3 into C3a and C3b. C3b also has a binding site for FB, allowing cleavage by FD, resulting in the second C3 convertase of AP, C3bBb. Additional C3b molecules are able to bind to the C3bBb complex to form C3bBb3bn, which exerts C5 convertase activity. Both C5 convertases, LP/CP and AP, cleave the C5 component into C5a and C5b. Newly formed C5b reacts with C6 to form the stable C5b6 complex that recruits C7 resulting in a hydrophobic complex that targets the membrane (mC5b-7). Membrane insertion is initiated upon binding of C8 (C5b-8) and 12–18 copies of C9 polymerize to form the membrane attack complex (MAC) that induces lysis of target membranes. In addition, as a product of all pathways being activated, the small fragments C4a, C3a, and C5a are formed, which are important anaphylatoxins, attracting and activating inflammatory cells to the activation site, such as neutrophils, monocytes, macrophages, and dendritic cells.

molecules on the trypomastigote’s surface, such as *T. cruzi* calreticulin (TcCRT) (Ferreira et al., 2004a; Valck et al., 2010; Sosoniuk et al., 2014), *T. cruzi* complement regulatory protein (TcCRP) or Gp160 (Norris et al., 1989; Norris and Schrimpf, 1994), *T. cruzi* complement C2 receptor inhibitor trispanning (TcCRIT) (Cestari et al., 2008), gp58/68 (Fischer et al., 1988) and T-DAF (Tambourgi et al., 1993). In addition, it has been shown that *T. cruzi* metacyclic trypomastigote forms induce membrane-derived vesicles (microvesicles) from host cells, which interact with C3 convertase, resulting in inhibition of complement activation and increased parasite survival, as well as eukaryotic cell invasion (Cestari et al., 2012). Moreover, it has been reported that microvesicles, derived from the host cell membrane and also secreted by *T. cruzi*, can fuse thereby increasing host cell invasion (Ramírez et al., 2016) (Table 1). The molecules and microvesicles involved in *T. cruzi* evasion from the complement system will be covered in more detail (Figure 4).

**T. cruzi Calreticulin (TcCRT)**

*Trypanosoma cruzi* calreticulin (TcCRT) is a 45 kDa calcium-binding protein that is primarily expressed in the ER of infective trypomastigotes. Upon infection, TcCRT is translocated from the RE to the emerging area of the flagellum on the plasma membrane surface (Ferreira et al., 2004a,b; González et al., 2015). Interestingly, this area has been shown to be the initial contact with the host plasma membrane (González et al., 2015).
TcCRT expressed on the *Trypanosoma cruzi* trypomastigote’s surface is able to bind to host PRMs, similar to C1q, MBL (Ferreira et al., 2004b; Ramírez et al., 2011) and ficolins (Sosoniuk et al., 2014) interfering in the activation of the CP and LP. TcCRT also likely enhances the rate of the internalization of *T. cruzi* trypomastigotes by host cells (Ramírez et al., 2011, 2012).

*Trypanosoma cruzi* calreticulin was initially named Tc45 and described as a polypeptide present in lysates of epimastigotes and trypanomastigotes. It was revealed to have an immunogenic role in the induction of specific antibodies in *T. cruzi*-infected mice (Ramos et al., 1991) and in human CD ( Aguillón et al., 1997). Tc45 was subsequently characterized as *T. cruzi* calreticulin (TcCRT) as gene sequencing showed homology with calreticulin genes of other species ( Aguillón et al., 2000). Later, TcCRT was found to exhibit a high homology with HuCRT, a multifunctional 46 kDa protein present predominantly in the ER and subcellular compartments, as well as in the plasma membrane (Ferreira et al., 2004a). Extracellular HuCRT has been reported to contribute to cell adhesion to the extracellular matrix and to facilitate the uptake of apoptotic and cancerous cells by phagocytes (Lu et al., 2015). The molecule may act as a receptor for the collagen-like domain of C1q and MBL, promoting phagocytosis through C1qR (Stuart et al., 1997). In fact, the role of C1q in the invasion of mononuclear phagocytes and fibroblasts by *T. cruzi* trypanomastigotes has previously been demonstrated (Rimoldi et al., 1989). This parasite-derived molecule was later identified in infective trypanomastigotes as TcCRT (Ferreira et al., 2004b) and its activity is considered one of the strategies that mediates *T. cruzi* uptake by mammalian phagocytic cells, mimicking the process of apoptotic cells ingestion (Ramírez et al., 2011).

In the early stages of infection, TcCRT is able to bind to the carbohydrate-recognition domain of MBL resulting in abrogation of interaction with its natural ligands and the collagen domain of Ficolin-2, preventing C4 activation and impairing further activation of the LP (Ferreira et al., 2004b; Sosoniuk et al., 2014). This property, however, is not shared by Ficolin-3 (Sosoniuk et al., 2014). During the late stages of *T. cruzi* infection the CP can be activated in the presence of specific *T. cruzi* antibodies, as mentioned earlier. Ferreira et al. (2004b) have demonstrated using hemolytic assays that recombinant TcCRT binds to C1q collagenous tails, impairing the activation of the CP. Subsequent studies showed that TcCRT competes with the (C1r-C1s)2 tetrameric complex for binding in the collagenous C1q tails and interferes in the capacity of C1s to activate C4 in a calcium-independent manner (Valck et al., 2010). In summary, TcCRT has been shown to be involved in the internalization of *T. cruzi* into mammalian cells, which increases infectivity. It is also known to be an important regulator of both the LP and CP.

**Trypanomastigote Decay-Accelerating Factor (T-DAF)**

The T-DAF is an 87–93 kDa glycoprotein present on the surface of metacyclic and tissue-culture-derived trypanomastigote forms of *T. cruzi* that mimics the activity of the complement regulatory protein DAF (Tambourgi et al., 1993). T-DAF regulates the activation of the AP, CP, and probably LP, by interfering in the assembly of C3 convertases.

During *T. cruzi* infection, the three complement pathways are activated culminating with the formation of C3 convertase that cleaves the central component C3. The presence of molecules modulating the C3 convertase of the CP in trypanomastigote but not epimastigote forms of *T. cruzi* surface was first described by Kipnis et al. (1986). It was subsequently demonstrated in a supernatant culture of trypanomastigotes that these modulator molecules ranged between 86 and 155 kDa in size, that were enriched for proteins of 86–98 kDa absent in epimastigotes. They were shown to accelerate the decay of both the AP and CP C3 convertases *in vitro* by interfering in the binding of factor B with C3b, or in the formation of C4b2a, respectively. Because of the similar behavior to human complement regulatory DAF the authors called these modulators as analogous to DAF (Rimoldi et al., 1988). In the same year Joiner et al. (1988) characterized biochemically an 87–93 kDa factor produced by *T. cruzi*.
FIGURE 4 | Complement evasion by strategies of *T. cruzi* trypomastigotes forms. TcCRT blocks CP and LP binding to C1q, MBL and Ficolin-2; T-DAF and Gp58/68 block CP C3 convertase assembly; TcCRIT blocks CP and LP binding to C2; gp58/68 blocks AP C3 convertase binding to factor B; and MV inhibit CP and LP C3 convertase assembly. AP, Alternative pathway; LP, Lectin pathway; and CP, Classical pathway.

Trypanosoma cruzi complement regulatory protein (TcCRP)

Trypanosoma cruzi complement regulatory protein (TcCRP), also called Gp160, is a 160 kDa glycoprotein anchored into trypomastigote membranes (Norris et al., 1989) via glycosylphosphatidylinositol linkage (Norris and Schrimpf, 1994). It is also spontaneously shed in culture from trypomastigotes (Norris et al., 1991). Both membrane and soluble forms of TcCRP are able to bind to C3b and C4b inhibiting the formation of the AP and CP C3 convertases.
Trypanosoma cruzi complement regulatory protein was initially purified and partially characterized by Norris et al. (1989) as Gp160 because of its molecular weight, and was found to be expressed in membrane extracts of both metacyclic and tissue-culture-derived T. cruzi trypomastigotes, but absent in insect epimastigotes or intracellular amastigotes. Norris and Schrimpf (1994) purified and characterized the membrane form of TcCRP having the glycolipid anchor attached which presented a molecular mass of 185 kDa. The conversion of the 185-kDa membrane form to the 160-kDa form was suggested to be the result of cleavage by endogenous phospholipase C. Both soluble (160 kDa) and membrane TcCRP forms (185 kDa) are able to bind C3b and C4b preventing the assembly of proteolytically active C3 convertase inhibiting both AP and CP activation (Norris et al., 1991; Norris and Schrimpf, 1994). It was then demonstrated that the TcCRP had similar activity to human CRP and DAF, being considered a member of the C3/C4 binding family of complement regulatory proteins, which provided infectious trypomastigotes another mean of evading the harmful effects of complement (Norris et al., 1991). Since TcCRP binds C4b, LP activation could be also affected at the same level. Moreover, anti-TcCRP lytic antibodies were present in the sera of T. cruzi-infected patients. Interesting, in the presence of anti-TcCRP antibodies the interaction between TcCRP and C3b was blocked allowing the AP C3 convertase assembly and parasite lysis (Norris et al., 1991).

Norris (1996) demonstrated that following the binding to C3b, TcCRP was released from the T. cruzi trypomastigote membrane by proteolytic cleavage, and these findings represented a new alternative mechanism of T. cruzi in evading complement activation. Interestingly, epimastigote forms transfected with a cDNA encoding full-length recombinant TcCRP were protected from complement-mediated lysis, confirming the role of TcCRP as a complement resistance factor of T. cruzi trypomastigotes (Norris et al., 1997; Norris, 1998). Recently, Henrique et al. (2016) demonstrated that surface expression of TcCRP differs among parasite strains, with a tendency of higher expression levels in the most virulent T. cruzi strains. In summary, TcCRP is directly involved in the evasion of T. cruzi from complement lysis by binding to C3b and C4b and consequently inhibiting both the AP, CP, and probably LP.

T. cruzi Complement C2 Receptor Inhibitor Trispanning (TcCRIT)

Trypanosoma cruzi complement C2 receptor inhibitor trispanning (TcCRIT) is a 32 kDa transmembrane protein that presents a sequence homology with the C4 beta-chain, the binding site of C2. Thus, TcCRIT inhibits the cleavage of C2 by C1s or MASP-2 and consequently prevents C3 convertase formation by competing with C4 (Inal, 1999; Inal and Schifferli, 2002; Cestari et al., 2012). TcCRIT is mainly expressed in complement resistant trypomastigote forms of T. cruzi regulating the activation of both the CP and LP (Inal, 1999; Inal et al., 2005).

The complement C2 receptor inhibitor trispanning (CRIT) was first described in the tegument of Schistosoma haematobium and subsequently S. mansoni (Inal, 1999; Inal and Sim, 2000) as a phosphorylated tyrosine molecule named TOR that inhibited C2 cleavage by C1s inhibiting the CP activation. It was then characterized as a novel complement regulator, and named CRIT (Inal and Sim, 2000). S. haematobium TOR (Sh-TOR) protein sequencing showed a long cytoplasmic tail with several consensus phosphorylation sites for enzymes, such as tyrosine kinases, characteristically associated with membrane receptors (Inal, 1999). Later, it was demonstrated that the Sh-TOR synthetic peptide pre-incubated with C2 inhibited the CP activation both in vitro (Inal and Schifferli, 2002) and in vivo (Inal et al., 2003) by competing with C4b (which presents some sequence identity to the first extracellular domain of Sh-TOR) (Inal and Sim, 2000). CRIT is highly conserved in Schistosoma species, T. cruzi strains, and mammals (Inal, 1999, 2005). Interestingly, both the Trypanosoma parasite and its human host share a receptor for CRIT, with a complement regulatory function (Inal et al., 2005).

Complement C2 receptor inhibitor trispanning protein was later shown to be expressed in the infective stage of T. cruzi preventing the lytic activity of NHS. In addition, overexpression of TcCRIT in transgenic epimastigotes increased the resistance to complement-mediated killing in the presence of non-immune NHS, blocking both the CP and LP. However, when epimastigotes were treated with exogenous C2 the complement activity was restored (Cestari et al., 2008). Although metacyclic trypomastigotes and epimastigotes differ regarding complement resistance, MBL, Ficolin-2 and Ficolin-3 are able to bind to glycosylated proteins on the surface of both parasites forms. However, only metacyclic trypomastigotes were shown to resist complement killing due to high expression levels of TcCRIT. TcCRIT circumvent LP activation through binding to C2, inhibiting its cleavage by MASP-2 and C3 convertase formation (Cestari et al., 2009). In summary, TcCRIT interferes in the activation of the LP and CP by binding to C2 and preventing its cleavage by the serine proteases C1s and MASP2, thereby evading both initial branches of complement activation. This leads to resistance against complement-mediated cell lysis, allowing T. cruzi survival and cell invasion.

T. cruzi Complement Regulatory gp58/68

The T. cruzi complement regulatory gp58/68 is a glycoprotein of an apparent molecular weight of 58 kDa (non-reduced) and 68 kDa (reduced) (Fischer et al., 1988) that is expressed on the parasite surface or can be released by trypomastigotes in culture (Ouaissi et al., 1988; Velge et al., 1988). It is part of the T. cruzi fibronectin/collagen receptor which consists of two molecules of 80–85 kDa and 58–68 kDa with an important role in the attachment of trypomastigote forms to mammalian cells (Ouaissi et al., 1984, 1986; Velge et al., 1988). Gp58/68 acts as a T. cruzi complement regulatory protein shown to inhibit the formation of cell-bound and fluid-phase AP C3 convertases (Fischer et al., 1988).

Gp58/68 was first identified in studies on the biological function of T. cruzi fibronectin receptors (TcFnR) by Ouaissi et al. (1984). Human fibronectin purified from blood were
shown to bind specifically to \textit{T. cruzi} trypomastigotes and to be involved in cell-parasite interaction. Anti-fibronectin antibodies were able to eradicate \textit{in vitro} fibroblast infection by \textit{T. cruzi} trypomastigotes (Ouaissi et al., 1984). The isolation and functional characterization of TcFnR were later achieved using immunoprecipitation assays, which identified the 85 kDa protein. Both affinity-purified TcFnR and anti-TcFnR antibodies exerted an inhibitory effect in the infection of fibroblasts by \textit{T. cruzi} trypomastigotes (Ramirez et al., 2016). Subsequent studies characterized the other part of the fibronectin/collagen receptor, the collagen receptor, and showed that the same \textit{T. cruzi} receptor binds to the host fibronectin and/or collagen, and that both the 80–85 kDa and 58/68 kDa glycoproteins are part of the same receptor (Velge et al., 1988). In the same year, the gp58/68 was purified by affinity chromatography from lysate of both culture and peripheral blood \textit{T. cruzi} trypomastigotes and named according to its molecular weight (Fischer et al., 1988). This \textit{T. cruzi} glycoprotein was able to inhibit the formation of cell-bound AP C3 convertase by preventing the initial association of FB with surface fixed C3b in a dose dependent manner. Moreover, gp58/68 was also shown to restrict the formation of fluid-phase AP C3 convertase by the consumption of fluid-phase FB (Fischer et al., 1988). In summary, gp58/68 is part of a fibronectin/collagen receptor of \textit{T. cruzi} that has an important role in the interaction of \textit{T. cruzi} with mammalian cells and confers the parasite's ability to evade AP complement activation by inhibiting FB/C3b interaction.

**Host and \textit{T. cruzi} Microvesicles**

Microvesicles (MVs) are 100–1000 nm vesicles originating from the plasma membrane and are released by a large number of cells from the blood, immune system, epithelial and endothelial tissues, among others (Evans-Osses et al., 2013). MVs are involved in intercellular communication owing to their capacity to transfer proteins, lipids, and nucleic acids, thereby influencing various physiological and pathological functions of both the recipient and parent cell (Yáñez-Mó et al., 2015). MVs are known to be released by different pathogens such as bacteria, fungus, and parasites, including \textit{T. cruzi} (Silveira et al., 1979; Gonçalves et al., 1991; Geiger et al., 2010), which may carry virulence factors to host cells promoting the dissemination of the pathogen (Deatheragea and Cooksona, 2012; Barteneva et al., 2013). Host mammalian cells infected with \textit{T. cruzi} release MVs that interfere in CP and LP C3 convertases assembly on the parasite's surface, leading to the inhibition of its catalytic activity (Cestari et al., 2012) and consequently eliminating complement activation. Recent findings have demonstrated that interaction between \textit{T. cruzi} trypomastigote and epimastigote forms with host cells also can induce MVs formation (Ramirez et al., 2016).

New insight into the mechanisms of complement immune evasion by \textit{T. cruzi} were gain when Cestari et al. (2012) reported secretion of host MVs induced by parasitic infection. At the beginning of infection, metacyclic trypomastigotes induced the release of MVs from immune cells, such as lymphocytes, monocytes, and macrophages in a calcium-dependent process (Cestari et al., 2012). Under experimental conditions MVs were shown to strongly inhibit C3b deposition. However, C4b deposition was not significantly inhibited. These findings suggest that MVs interfered on complement at C3 level. In addition, MVs were shown to bind LP and CP C3 convertase complexes on the surface of \textit{T. cruzi} inhibiting complement-mediated lysis and favoring the invasion of host cells. Moreover, C1q, Ficolin-2, and Ficolin-3 were also found to bind to MVs but did not impair parasite recognition by these PRMs. It has also been shown that MVs derived from lymphocytes and monocytes carry TGF-β, an important cytokine that enhances \textit{T. cruzi} cell invasion and protects the parasite against complement-mediated lysis (Cestari et al., 2012). Recently, the release of MVs derived from infective (metacyclic trypomastigote and tissue-culture-derived trypomastigote) and non-infective (epimastigote) parasites, and their interaction with host cells was demonstrated. In addition, infective and non-infective \textit{T. cruzi} forms were shown to induce different levels of MV release from host cells. Moreover, the fusion of MVs derived from both host cell and parasite was demonstrated, and this phenomenon appears to facilitate contact between \textit{T. cruzi} and host cell plasma membranes, and probably membrane fusion. Thus, MVs released during interaction of the parasite with host cells were able to increase host cell invasion by metacyclic trypomastigotes (Ramirez et al., 2016). In summary, interaction between \textit{T. cruzi} and host cells prompt the release of MVs from both parasite and host cells and this phenomenon may contribute to evasion of CP and LP complement activation and to increase host cell infection. Thus, both host and parasite MVs probably have a potential immunomodulatory effect in the pathogenesis of \textit{T. cruzi} infection.

**IMMUNOMODULATORY PERSPECTIVES**

Although it has been suggested that the effectiveness of the etiological treatment for CD is inversely proportional to the duration of \textit{T. cruzi} infection, the success of trypanosomatid drugs in preventing clinical progression to symptomatic forms is still controversial. Considering that \textit{T. cruzi} makes use of several strategies to evade the host immune system in order to establish the infection, these molecules involved in evasion mechanisms could be interesting therapeutic targets to be explored in the context of prevention and treatment of CD. Immunomodulatory therapies could be based on the use of antibodies against overexpressed \textit{T. cruzi} molecules, such as TcCRT, T-DAF, TcCRP, TcCRTIT, and gp58/68. For instance, \textit{T. cruzi} complement regulatory proteins, such as TcCRT, T-DAF, and gp58/68, may also be targets of anti-\textit{T. cruzi} lytic antibodies (as reviewed by Krautz et al., 2000) and could be used as indicators of drug efficacy in \textit{T. cruzi} infection and parasite clearance, as observed by anti-TcCRT and anti-T-DAF detected in sera of CD patients (Norris et al., 1994; Tambourgi et al., 1995). In addition, the association of MBL deficiency with protection against the development and progression of chronic CD cardiomyopathy (Luz et al., 2016) highlighted a potential marker for disease progression. Moreover, an interesting therapeutic approach to control the early stage of \textit{T. cruzi} infection in patients with MBL deficiency and defects in LP activation may be the restitution of MBL or other PRMs involved in complement activation. Thus,
new investigations are needed to explore which *T. cruzi* evasion molecules could be potential immunotherapeutic targets that could contribute to change the pathophysiological progression of this neglected disease.

**CONCLUSION**

The current knowledge on complement evasion strategies used by *T. cruzi* highlights the importance of the LP, AP, and CP as crucial components in the first line of defense against this parasitic infection. However, *T. cruzi* infective forms are able to regulate and inhibit the complement activation early in the proteolytic cascade by expressed and/or released regulator molecules thereby circumventing complement’s harmful effects. Thus, complement becomes prey of *T. cruzi* and has a bad day. Understanding these complement evasion strategies is crucial for the development of innovative strategies in the battle against *T. cruzi* infection and may pave the way for novel immunotherapies.

**AUTHOR CONTRIBUTIONS**

KL, LB, and AA participated in the design and writing of the manuscript. IdM-R: participated in the design, coordination, and manuscript writing. KL developed the graphic design of all figures.

**ACKNOWLEDGMENTS**

This work was supported by research grants from Coordenação de Aperfeiçoamento de Pessoal Superior (CAPES Edital Parastitologia Básica 32/2010) and from Conselho Nacional de Desenvolvimento Científico e Tecnológico to IM-R (CNPq).

**REFERENCES**

Abrahamsohn, I. A., and Dias da Silva, W. (1977). Antibody dependent cell-mediated cytotoxicity against *Trypanosoma cruzi*. *Parasitology* 75, 317–323. doi: 10.1017/S0031182000051866

Aguillón, J. C., Ferreira, L., Pérez, C., Colombo, A., Molina, M. C., Wallace, A., et al. (2000). Tc45, a dimorphic *Trypanosoma cruzi* immunogen with variable chromosomal localization, is calreticulin. *Am. J. Trop. Med. Hyg.* 63, 306–312.

Aguillón, J. C., Harris, R., Molina, M. C., Colombo, A., Cortés, C., Hermosilla, T., et al. (1997). Recognition of an immunogenetically selected *Trypanosoma cruzi* antigen by seropositive chagasic human sera. *Acta Trop.* 63, 159–166. doi: 10.1016/S0001-706X(96)00619-5

Alberti, S., Marques, G., Camprubi, S., Merino, S., Tomas, J. M., Vivanco, F., et al. (1993). Clq binding and activation of the complement classical pathway by *Klebsiella pneumoniae* outer membrane proteins. *Infect. Immun.* 61, 852–860.

Barteneva, N. S., Maltsev, N., and Vorobjov, I. (2013). Microvesicles and intercellular communication in the context of parasitism. *Front. Cell. Infect. Microbiol.* 3:49. doi: 10.3389/fcimb.2013.00049

Beltrame, M. H., Catarino, S. J., Goeldner, I., Boldt, A. B. W., and Messias-Reason, I. J. (2015). The lectin pathway of complement and rheumatic heart disease. *Front. Pediatr.* 2:148. doi: 10.3389/fped.2014.00148

Bern, C., and Montgomery, S. P. (2009). An estimate of the burden of chagas disease in the united states. *Clin. Infect. Dis.* 49, e52–e4. doi: 10.1086/605091

Berm, C., Montgomery, S. P., Herwaldt, B. L., Marin-neto, J. A., Maguire, J. H., Acquatella, H., et al. (2007). Evaluation and treatment of chagas disease in the united states a systematic review. *JAMA* 298, 2171–2181. doi: 10.1001/jama.298.18.2171

Biolo, A., Ribeiro, A. L., and Clausell, N. (2010). Chagas cardiomyopathy-where do we stand after a hundred years? *Prog. Cardiovasc. Dis.* 52, 300–316. doi: 10.1016/j.pcad.2009.11.008

Boldt, A. B. W., Luz, P. R., and Messias-Reason, J. I. T. (2011). MASPS2 haplotypes are associated with high risk of cardiomyopathy in chronic chagas disease. *Clin. Immunol.* 140, 63–70. doi: 10.1016/j.clim.2011.03.008

Bonney, K. M. (2014). Chagas disease in the 21st century: a public health success or an emerging threat? *Parasite* 21, 11. doi: 10.1051/parasite/2014012

Buscaglia, C. A., Campo, V. A., Frasch, A. C. C., and Di Noia, J. M. (2006). *Trypanosoma cruzi* surface mucins: host-dependent coat diversity. *Nat. Rev. Microbiol.* 4, 229–236. doi: 10.1038/nrmicro1351

Carroll, M. V., and Sim, R. B. (2011). Complement in health and disease. *Adv. Drug Deliv. Rev.* 63, 965–975. doi: 10.1016/j.addr.2011.06.005

Cestari, I., Ansa-Addo, E., Deolindo, P., Inal, J. M., and Ramirez, M. I. (2012). *Trypanosoma cruzi* immune evasion mediated by host-derived microvesicles. *J. Immunol.* 188, 1942–1952. doi: 10.4049/jimmunol.1102053

Cestari, I., Evans-Osses, I., Schlabach, L. J., Messias-Reason, I., and Ramirez, M. I. (2013). Mechanisms of complement lectin pathway activation and resistance by trypanosomatid parasites. *Mol. Immunol.* 53, 328–334. doi: 10.1016/j.molimm.2012.08.015

Cestari, I., and Ramirez, M. I. (2010). Inefficient complement system clearance of *Trypanosoma cruzi* metacyclic trypomastigotes enables resistant strains to invade eukaryotic cells. *PLoS ONE* 5:e9721. doi: 10.1371/journal.pone.0009721

Cestari, I. S., Evans-Osses, I., Freitas, J. C., Inal, J. M., and Ramirez, M. I. (2008). Complement C2 receptor inhibitor trispanning confers an increased ability to resist complement-mediated lysis in *Trypanosoma cruzi*. *J. Infect. Dis.* 198, 1276–1283. doi: 10.1086/592167

Cestari, I. S., Krarup, A., Sim, R. B., Inal, J. M., and Ramirez, M. I. (2009). Role of early lectin pathway activation in the complement-mediated killing of *Trypanosoma cruzi*. *Mol. Immunol.* 47, 426–437. doi: 10.1016/j.molimm.2009.08.030

Cochrane, C. G., and Müller-Eberhard, H. J. (1968). The derivation of two distinct anaphylatoxin activities from the third and fifth components of human complement. *J. Exp. Med.* 127, 371–386. doi: 10.1084/jem.127.2.371

Deatherage, B. L., and Cooksона, B. T. (2012). Membrane vesicle release in bacteria, eukaryotes, and archaea: a conserved yet underappreciated aspect of microbial life. *Infect. Immun.* 80, 1948–1957. doi: 10.1128/IAI.06014-11

Dias da Silva, W., Eisele, J. W., and Lepow, I. H. (1967). Complement as a mediator of inflammation. III. Purification of the activity with anaphylatoxins generated by interaction of the first four components of complement and its identification as a cleavage product of C3. *J. Exp. Med.* 126, 1027–1048. doi: 10.1084/jem.126.6.1027

Dias da Silva, W., and Lepow, I. H. (1967). Complement as a mediator of inflammation. II. Biological properties of anaphylatoxins prepared with purified components of human complement. *J. Exp. Med.* 125, 921–946. doi: 10.1084/jem.125.5.921

Dvorak, J. A., and Howe, C. L. (1976). The attraction of *Trypanosoma cruzi* to vertebrate cells In *Vitro*. *J. Protozool.* 23, 534–537. doi: 10.1126/science.294.5546.1483

Dvorak, J. A., and Hyde, T. P. (1973). *Trypanosoma cruzi*: interaction with vertebrate cells in vitro. *Exp. Parasitol.* 34, 268–283. doi: 10.1016/0044-8894(73)90087-8

European Centre for Disease Prevention and Control (ECDC) (2014). *Assessing the Burden of Key Infectious Diseases Affecting Migrant Populations in the EU/EEA*. Stockholm: European Centre for Disease Prevention and Control. doi: 10.2900/28792

Evans-Osses, I., Messias-Reason, I., and Ramirez, M. I. (2013). The emerging role of complement lectin pathway in trypanosomatids: molecular bases in activation, genetic deficiencies, susceptibility to infection, and complement system-based therapeutics. *Sci. World J.* 2013:675898. doi: 10.1155/2013/675898
Ferreira, V., Molina, M. C., Valck, C., Rojas, A., Aguilar, L., Ramírez, G., et al. (2004a). Role of calreticulin from parasites in its interaction with vertebrate hosts. Mol. Immunol. 40, 1279–1291. doi: 10.1016/j.molimm.2003.11.018

Ferreira, V., Valck, C., Sánchez, G., Gingras, A., Tzima, S., Molina, M. C., et al. (2004b). The classical activation pathway of the human complement system is specifically inhibited by calreticulin from Trypanosoma cruzi. J. Immunol. 172, 3042–3050. doi: 10.4049/jimmunol.172.5.3042

Fischer, E., Ouaisi, M. A., Velget, P., Cornette, J., and Kazatchkine, M. D. (1988). Gp 58/68, a prasite component that contributes to the escape of the trypomastigote form of *T. cruzi* from damage by the human alternative complement pathway. Immunology 65, 299–303.

Flierman, R., and Daha, M. R. (2007). The clearance of apoptotic cells by complement. Immunobiology 212, 363–370. doi: 10.1016/j.imbio.2006.11.005

Frederiksen, P. D., Thiel, S., Larsen, C. B., and Jensenius, J. C. (2005). M-Ficolin, an innate immune defence molecule, binds patterns of acetyl groups and activates complement. Scand. J. Immunol. 62, 462–473. doi: 10.1111/j.1365-3083.2005.01685.x

Geiger, A., Hirtz, C., Bécue, T., Bellard, E., Centeno, D., Gargani, D., et al. (2010). Exocytosis and protein secretion in *Trypanosoma BMC Microbiol*. 10:20. doi: 10.1186/1471-2180-10-20

González, A., Valck, C., Sánchez, G., Härtel, S., Mansilla, J., Ramírez, G., et al. (2011). Trypanosoma cruzi: shedding of surface antigens as membrane vesicles. Exp. Parasitol. 72, 43–53. doi: 10.1016/j.exppara.2010.01.009

Geiser, K., Fritzsche, J., Ziebarth, G., Tzima, S., Valck, C., Sánchez, G., et al. (2015). Trypanosoma cruzi calreticulin topographical variations in parasites infecting murine macrophages. Am. J. Trop. Med. Hyg. 92, 887–897. doi: 10.4269/ajtmh.14-0497

Gout, E., Garlatti, V., Smith, D. F., Lacroix, M., Dumestre-Pérad, C., Lunardi, T., et al. (2010). Carbohydrate recognition properties of human ficolins: glycan array screening reveals the sialic acid binding specificity of M-Ficolin. J. Biol. Chem. 285, 6612–6622. doi: 10.1074/jbc.M109.065854

Henrique, P. M., Marques, T., da Silva, M. V., Nascentes, G. A. N., de Oliveira, C. F., Rodrigues, V. I., et al. (2016). Correlation between the virulence of *T. cruzi* strains, complement regulatory protein expression levels, and the ability to elicit lytic antibody production. Exp. Parasitol. 170, 66–72. doi: 10.1016/j.exppara.2016.09.001

Hidron, A., Vogenthaler, N., Santos-Preciado, J. I., Rodríguez-Morales, A. J., Franco-Paredes, C., and Rassi, A. (2010). Cardiac involvement with parasitic infections. Clin. Microbiol. Rev. 23, 324–349. doi: 10.1128/CMR.00054-09

Iida, K., Whitlow, M. B., and Nussenzweig, V. (1989). Amastigotes of *Trypanosoma cruzi* escape destruction by the terminal in the absence of antibody, the alternative pathway of the complement system can function as a first barrier in preventing infection. however, certain microorganisms have developed mec. J. Immunol. 1445, 283–298. doi: 10.1016/S0167-4781(99)00051-2

Inal, J. M. (1999). Schistosoma TOR (trispanning Orphan Receptor), a novel, specific inhibitory receptor. Complement system part Iñmolecular mechanisms of activation and regulation. Immunobiology 212, 271–284. doi: 10.1016/S0167-4781(99)00052-7

Inal, J. M. (2004). Complement C2 receptor inhibitor trispanning: a novel human complement inhibitory receptor. J. Immunol. 174, 356–366. doi: 10.4049/jimmunol.174.1.356

Inal, J. M., and Schifferli, J. A. (2002). Complement C2 receptor inhibitor trispanning and the Beta-chain of C4 share a binding site for complement C2. J. Immunol. 168, 5213–5221. doi: 10.4049/jimmunol.168.10.5213

Inal, J. M., Schneider, B., Armanini, M., and Schifferli, J. A. (2003). A peptide derived from the parasite receptor, complement C2 receptor inhibitor trispanning, suppresses immune complex-mediated inflammation in mice. J. Immunol. 170, 4310–4317. doi: 10.4049/jimmunol.170.8.4310

Inal, J. M., and Sim, R. B. (2000). A schistosoma protein, Sh-TOR, is a novel inhibitor of complement which binds human C2. FEBS Lett. 470, 131–134. doi: 10.1016/S0014-5793(00)01304-1

Joiner, K., Sher, A., Gaither, T., and Hammer, C. (1986). Evasion of alternative complement pathway by *Trypanosoma cruzi* results from inefficient binding of factor-B. Proc. Natl. Acad. Sci. U.S.A. 83, 6593–6597. doi: 10.1073/pnas.83.17.6593

Joiner, K. A., DaSilva, W. D., Rimoldi, M. T., Hammer, C. H., Sher, A., and Kipnis, T. L. (1988). Biochemical characterization of a factor produced by trypomastigotes of *Trypanosoma cruzi* that accelerates the decay of complement C3 convertases. J. Biol. Chem. 263, 11327–11335

Keshi, H., Sakamoto, T., Kawai, T., Ohtani, K., Katoh, T., Jang, S., et al. (2006). Identification and characterization of a novel human collectin CL-K1. Microbiol. Immunol. 50, 1001–1013. doi: 10.1111/j.1348-4202.2006.tb03868.x

Kipnis, T. L., Krettli, A. U., and Da Silva, W. D. (1985). Transformation of trypomastigote forms of *Trypanosoma cruzi* into activators of alternative complement pathway by immune IgG fragments. Scand. J. Immunol. 22, 217–226. doi: 10.1111/j.1365-3083.1985.tb01874.x

Lee, B. Y., Bacon, K. M., Bottazzi, M. E., and Hotez, P. J. (2013). Global economic burden of chagas disease: a computational simulation model. *Lancet Infect. Dis.* 13, 342–348. doi: 10.1016/S1473-3099(13)70002-1

Levine, N. D., Corliss, J. O., Cox, F. E. G., Deroux, G., Grain, J., Honigberg, B. M., et al. (1980). A newly revised classification of the protozoa. *J. Protozool.* 27, 320–331. doi: 10.1128/JCP.00051-2

Liderkremer, R., and Bertello, L. (2001). Glycoinositolphospholipids, free and as anchors of proteins, in *Trypanosoma cruzi*. *Curr. Pharm. Des.* 7, 1165–1179. doi: 10.2174/1381612013397519

Lorincz, Z., Gál, P., Dobó, J., Cseh, S., Szlágyi, K., Ambrus, G., et al. (2000). The cleavage of two C1s subunits by a single active C1r reveals substantial flexibility of the C1s-C1r-C1s tetramer in the C1 complex. *J. Immunol.* 165, 2048–2051. doi: 10.4049/jimmunol.165.4.2048

Liu, Y. C., Weng, W. C., and Lee, H. (2015). Functional roles of calreticulin in cancer biology. *BioMed Res. Int.* 2015, 9. doi: 10.1155/2015/526524

Lobato, J. L., Singh, G. D., and Amsterdam, E. A. (2015). The epidemiology, clinical manifestations, and management of chagas heart disease. *Clin. Cardiol.* 38, 565–569. doi: 10.1002/clc.22421

Miller, G. W., and Nussenzweig, V. (1974). Complement as a regulator of interactions between immune complexes and cell membranes. *J. Immunol.* 113, 464–469.
Norris, K. A., Schrimpf, J. E., and Szabo, M. J. (1997). Identification of the gene
Norris, K. A., Galvao, L. M. C., Schrimpf, J. E., Cancado, J. R., and Krettli, A. U. (1998). Stable transfection of
Norris, K. A., Bradt, B., Cooper, N. R., and So, M. (1991). Characterization
Norris, K. A., Bradt, B., Cooper, N. R., and So, M. (1991). Characterization of a Trypanosoma cruzi binding protein with functional and genetic similarities to the human complement regulatory protein, decay-accelerating factor. J. Immunol. 147, 2240–2247.
Norris, K. A., Galvao, L. M. C., Schrimpf, J. E., Cancado, J. R., and Krettli, A. U. (1994). Humoral immune response to the Trypanosoma cruzi complement regulatory protein as an indicator of parasitologic clearance in human chagasis. Dis. Infect. Immun. 62, 4072–4074.
Norris, K. A., Harth, G., and So, M. (1989). Purification of a Trypanosoma cruzi membrane glycoprotein which elicits lytic antibodies. Infect. Immun. 57, 2372–2377.
Norris, K. A., and Remuzzi, G. (2013). Overview of complement activation and regulation. Mem. Inst. Oswaldo Cruz 108, 502. doi: 10.1590/S0074-027619880000931
Noris, M., and Remuzzi, G. (2013). Overview of complement activation and regulation. Mem. Inst. Oswaldo Cruz 108, 502. doi: 10.1590/S0074-027619880000931
Norris, K. A. (1988). Developmentally regulated expression by Trypanosoma cruzi of the hakata antigen, a member of the fibroblastin receptor superfamily. J. Exp. Med. 168, 222–224.
Norris, K. A. (1998). Developmentally regulated expression by Trypanosoma cruzi of the hakata antigen, a member of the fibroblastin receptor superfamily. J. Exp. Med. 168, 222–224.
Noris, M., and Remuzzi, G. (2013). Overview of complement activation and regulation. Mem. Inst. Oswaldo Cruz 108, 502. doi: 10.1590/S0074-027619880000931
Norris, K. A. (1988). Developmentally regulated expression by Trypanosoma cruzi of the hakata antigen, a member of the fibroblastin receptor superfamily. J. Exp. Med. 168, 222–224.
Norris, K. A. (1998). Developmentally regulated expression by Trypanosoma cruzi of the hakata antigen, a member of the fibroblastin receptor superfamily. J. Exp. Med. 168, 222–224.
Norris, K. A. (1998). Developmentally regulated expression by Trypanosoma cruzi of the hakata antigen, a member of the fibroblastin receptor superfamily. J. Exp. Med. 168, 222–224.
Norris, K. A. (1998). Developmentally regulated expression by Trypanosoma cruzi of the hakata antigen, a member of the fibroblastin receptor superfamily. J. Exp. Med. 168, 222–224.
Norris, K. A. (1998). Developmentally regulated expression by Trypanosoma cruzi of the hakata antigen, a member of the fibroblastin receptor superfamily. J. Exp. Med. 168, 222–224.
the first component of human complement by *Trypanosoma cruzi* Calreticulin. *Mol. Immunol.* 47, 1516ñ1521. doi: 10.1016/j.molimm.2010.01.019

van Lookeren, C. M., Wiesmann, C., and Brown, E. J. (2007). Macrophage complement receptors and pathogen clearance. *Cell Microbiol.* 9, 2095ñ2102. doi: 10.1111/j.1462-5822.2007.00981.x

Velge, P., Ouassiss, M. A., Cornette, J., Afchain, D., and Capron, A. (1988). Identification and isolation of *Trypanosoma cruzi* trypomastigote collagen-binding proteins: possible role in cell-parasite interaction. *Parasitology* 97(Pt 2), 255ñ268. doi: 10.1017/S0031182000058467

Walport, M. J. (2001). Complement first of two parts. *N. Engl. J. Med.* 344, 1058ñ1066.

Watanabe Costa, R., Silveira, J. F., and Bahia, D. (2016). Interactions between *Trypanosoma cruzi* secreted proteins and host cell signaling pathways. *Front. Microbiol.* 7:388. doi: 10.3389/fmicb.2016.00388

Weis, W. I., Drickamer, K., and Hendrickson, W. (1992). Structure of a C-Type mannose-binding protein complexed with an oligosaccharide. *Nature* 360, 127ñ134. doi: 10.1038/360127a0

Weitzel, T., Zulantay, I., Danquah, I., Hamann, L., Schumann, R. R., Apt, W., et al. (2012). Mannose-binding lectin and toll-like receptor polymorphisms and chagas disease in chile. *Am. J. Trop. Med. Hyg.* 86, 229ñ232. doi: 10.4269/ajtmh.2012.11-0539

World Health Organization [WHO] (2009). *Control and Prevention of Chagas Disease in Europe*. Geneva: World Health Organization, 69.

World Health Organization [WHO] (2010). *Working to Overcome the Global Impact of Neglected Tropical Diseases First WHO Report on Neglected Tropical Diseases*. Geneva: World Health Organization.

World Health Organization [WHO] (2015). Chagas disease in latin america: an epidemiological update based on 2010 estimates. *Wkly. Epidemiol. Rec.* 6, 33ñ44. doi: 10.2147/IBPC.S70402

Yáñez-Mó, M., Siljander, P. R. M., Andreu, Z., Zavec, A. B., Borràs, F. E., Buzas, E. I., et al. (2015). Biological properties of extracellular vesicles and their physiological functions. *J. Extracell. Vesicles* 4:27066. doi: 10.3402/jev.v4.27066

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The reviewer WDDS and handling Editor declared their shared affiliation, and the handling Editor states that the process nevertheless met the standards of a fair and objective review.

*Copyright © 2017 Lidani, Bavia, Ambrosio and de Messias-Reason. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*